Long Standing Crohn's Disease and Signet Ring Cell Carcinoma of the Ileum

by David M. Schwartzberg, H. Tarik Kirat, Feza H. Remzi

INTRODUCTION

Crohn's disease (CD) has been associated with malignant transformation into aggressive forms of small bowel adenocarcinoma. The overall incidence of small bowel adenocarcinoma is less than 2%. Signet ring cell carcinoma (SRCC) is an aggressive subtype and is associated with poor differentiation and a poor survival, often presenting as T4 lesions in Crohn's patients. Midsmall bowel CD is difficult to survey and subtle symptomatology maybe the only clue in deciding between biologic therapy or surgical intervention. Before deciding on medical therapy, including a

David M. Schwartzberg MD, H. Tarik Kirat MD, Feza H. Remzi MD FACS FASCRS Department of Surgery, Inflammatory Bowel Disease Center, New York University Langone Health, New York, NY number of possible biologic therapies, malignancy must be ruled out, or surgical resection must be offered.⁴

We report a case of SRCC in a patient with longstanding Crohn's disease who was suspected to have increasing symptoms secondary to Crohn's ileitis. Escalation of medical therapy failed to control his symptoms and operative intervention was ultimately required. Pathology revealed a poorly differentiated, pT4aN2M1 SRCC adenocarcinoma in the setting of active Crohn's disease. This case highlights the importance of considering malignant transformation of the small intestine in the setting of long-standing inflammatory bowel disease.

Case Report

A 63-year-old male with a 32-year history of Crohn's disease presented with increasing abdominal pain, fatigue, weight loss and intolerance to solid food.

A CASE REPORT

(continued from page 90)




Image 1. CT showing axial imaging of ileal inflammation showing an increase of ileal bowel wall inflammation to 16.9mm while on biologic therapy for Crohn's disease (brackets).

Historically he had been treated with budesonide and mesalamine only requiring sporadic corticosteroid tapers. Recent colonoscopy revealed a scarred ileocecal valve, which prompted initiation of infliximab. Ileal thickening (to 16.9mm) was noted on computed tomography (CT) ordered for persistent symptoms despite two months of infliximab treatment (Image 1). Aggressive inpatient therapy failed to control his symptoms and surgical intervention was recommended. Peritoneal implants were noted on the anterior abdominal wall; frozen section was positive for mucinous adenocarcinoma. En bloc resection was performed (Image 2). His final pathology showed a poorly differentiated, pT4N2M1 signet ring cell carcinoma measuring 23 cm in length. Mismatch repair was stable. There was metastatic lymph node spread (12 of 15 lymph nodes), lymphovascular and perineural invasion, omental and peritoneal metastasis. CDX2, CK20 and CK7 stains were positive. The surrounding bowel was consistent with active Crohn's disease.

practicalgastro.com



Image 2. Small bowel consistent with Crohn's disease and a 23cm length signet ring cell adenocarcinoma; note the tumor depots on the bowel wall (arrows).

Discussion

This case describes malignant transformation of the ileum to an aggressive form of small bowel adenocarcinoma, signet ring cell carcinoma, in a patient with long-standing Crohn's disease. The subtype of SRCC is rare with only one other case arising in the presence of Crohn's disease. SRCC originate from undifferentiated stem cells and are mucin secreting tumors with an abundance of intracellular mucin that peripherally displaces the nucleus. SRCC is most commonly found in the stomach and colon, with small bowel SRCC only occurring in 1.1% of reported cases. It is generally associated with poor-differentiation and T4 lesions with a reported 5-year overall survival of 16.1%.^{2,3}

Overall, small bowel adenocarcinoma is uncommon, and its symptoms non-specific. Its association with Crohn's disease, however, increases the risk 40 to 60-fold relative to the general population. Though adenocarcinoma is rare, and the exact mechanism of malignant degeneration unknown, malignancy must be ruled out prior to escalating medical therapy, especially in patients with long-standing CD.

Surveillance of CD is possible in upper and lower gastrointestinal disease. Small bowel disease is often difficult to access endoscopically, thus

A CASE REPORT

location of disease must factor into the treatment algorithm. The aggressive nature of small bowel adenocarcinoma, specifically SRCC, should be considered when small bowel CD fails to improve with escalating medical therapy, or long-standing disease becomes increasingly worrisome. Surgical resection may be the only opportunity for cure, and it must be considered to be diagnosed.¹¹.

References

- Shaukat A, Virnig DJ, Howard D, Sitaraman SV, Liff JM, Lederle FA. Cronh's disease and small bowel adenocarcinoma: A population-based case-control study. Cancer Epidemiol Biomarkers Prev; 20(6) June 2011
- Wu SG, Chen XT, Zhang WW, Sun JY, Li FY, He ZY, Pei XQ, Lin Q. Survival in signet ring cell carcinoma varies on primary tumor location: a Surveillance, Epidemiology, and End Results database analysis, Expert Review of Gastroenterology & Hepatology, 2018, V12, No.2, 209-214
- Grolleau C, Pote NM, Guedj NS, Zappa M, Theou-Anton N, Bouhnik Y, Panis U, Cazals-Hatem D. Small

- bowel adenocarcinoma complicating Crohn's diease: a single-centre experience emphasizing the importance of screening for dysplasia, Vichows Arch (2017) 471:611-617
- Bojic D, Markovic S. Terminal ileitis is not always Crohn's disease, Ann Gastroenterol. 2011; 24(4): 271–275
- Jess T, Loftus EV, Jr, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology 2006; 130:1039-46Cahill C, Gordon P,
- Petrucci A, Boutros M. Small bowel adenocarcinoma and Crohn's disease: Any further ahead than 50 years ago? World J Gastroenterol. 2014 Sep 7; 20(33): 11486– 11495.
- Carvalho JR, Tavares J, Goulart I, Moura dos Santos, P, Vitorino E, Ferreira C, Serejo F, Velosa J. Signet ring cell carcinoma, ileal Crohn disease or both?-A case of diagnsostic challenge
- Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management, J Crohns Colitis Vol 11, issue 1, Jan 2017, p3-25



A Token of Our APPreciation® for Our Loyal Readers

Download PRACTICAL GASTROENTEROLOGY to your Mobile Device Available for Free on iTunes, Google Play and Amazon

Add the App instantly to your iPad or iPhone:

http://itunes.apple.com/us/app/practical-gastroenterology/id525788285?mt=8&ign-mpt=uo%3D4

Add the App instantly to your Android:

https://market.android.com/details?id=com.texterity.android.PracticalGastroApp http://www.amazon.com/gp/product/B00820QCSE